Digestive health lab tests use blood, stool, and sometimes breath samples to look for clues related to anemia, dehydration, inflammation, infection, celiac disease, nutrient malabsorption, pancreatic enzyme problems, and hidden blood in stool. Common starting tests include a CBC, CMP, selected inflammation markers, iron studies, and celiac serology. Targeted tests may include fecal calprotectin, H. pylori stool antigen or urea breath testing, stool pathogen testing, pancreatic elastase, and FIT for appropriate colorectal-cancer screening. No single test explains every digestive symptom. Persistent or concerning symptoms may require examination, imaging, endoscopy, biopsy, or specialist evaluation.
This page explains how different specimens and testing methods fit together. For broader laboratory-testing literacy, use these foundational guides:
Digestive concerns often overlap with vitamin and nutrient deficiency tests, CBC and anemia blood tests, inflammation and autoimmune blood tests, and liver function tests. These guides help separate anemia, micronutrient, systemic-inflammation, and liver-related questions from intestine-specific stool testing.
| Core test or test group | Common specimen | Fasting or timing need | Primary purpose | Common use status | Major limitation |
|---|---|---|---|---|---|
| CBC | Blood | Usually none when ordered alone | Looks for anemia, white-cell changes, and platelet patterns | Common or first-line | Does not identify where bleeding, inflammation, or infection originates |
| CMP | Blood | Follow the ordering laboratory’s instructions; fasting may be requested when bundled with other tests | Assesses electrolytes, kidney markers, glucose, proteins, bilirubin, and selected liver enzymes | Common or first-line | Does not visualize the bowel, gallbladder, bile ducts, or pancreas |
| CRP and ESR | Blood | Usually none when ordered alone | Detects nonspecific systemic inflammation | Common or targeted, depending on the question | Cannot locate inflammation or diagnose IBD, infection, or another cause by itself |
| Celiac serology: tTG-IgA with total IgA | Blood | Testing is most informative while the patient is eating gluten; fasting is usually unnecessary unless other tests require it | Screens for celiac-type autoantibodies and checks whether an IgA-based result is interpretable | Risk-based or targeted | A gluten-free diet, IgA deficiency, mild disease, or immunosuppression may affect results; biopsy may still be needed |
| Fecal calprotectin | Stool | No fasting; follow collection and storage instructions | Assesses intestinal inflammatory activity | Risk-based, targeted, or monitoring | Does not by itself distinguish Crohn’s disease, ulcerative colitis, infection, or another inflammatory cause |
| H. pylori stool antigen or urea breath test | Stool or breath | Acid-suppressing medicines, antibiotics, and bismuth can affect accuracy; follow clinician and laboratory instructions | Looks for active H. pylori infection and can document eradication after treatment | Risk-based, targeted, or monitoring | A negative result can be false if preparation or timing is unsuitable |
| Stool pathogen testing | Stool | Collect the correct type of stool promptly and avoid contamination | Looks for selected bacteria, viruses, parasites, toxins, or microbial genetic material | Risk-based or targeted | Broad molecular panels may detect colonization or more than one organism; results require clinical context |
| Pancreatic elastase | Solid or semisolid stool | A watery sample can be falsely low because of dilution | Assesses pancreatic exocrine enzyme output when insufficiency is suspected | Risk-based or targeted | Performance is weaker in mild disease and in people with low pretest probability |
| FIT or high-sensitivity stool blood testing | Stool | Follow the kit; FIT generally does not require dietary restriction | Colorectal-cancer screening in eligible adults without symptoms | Risk-based screening | A positive result requires colonoscopy; it is not the right substitute for evaluating visible bleeding or black stool |
| Amylase and lipase | Blood | Preparation varies; acute severe pain should be evaluated promptly rather than delayed for routine outpatient testing | Supports evaluation of suspected acute pancreatic injury | Targeted or acute-care | Not routine wellness tests and not reliable stand-alone tests for chronic pancreatic insufficiency |
Each available test name below links directly to its current Ulta Lab Tests page. A link shows where the test can be reviewed or ordered; it does not mean that the test is appropriate for every symptom or that it can establish a diagnosis by itself.
| Testing question | Linked Ulta Lab Tests page | Specimen | Typical role |
|---|---|---|---|
| Blood counts and anemia | Complete Blood Count with Differential and Platelets | Blood | Common starting test |
| Metabolic, electrolyte, protein, kidney, and liver context | Comprehensive Metabolic Panel | Blood | Common starting test |
| Systemic inflammation | C-Reactive Protein and Sedimentation Rate | Blood | Targeted context tests |
| Iron deficiency or blood-loss pattern | Ferritin, Iron and TIBC, Transferrin, and Reticulocyte Count | Blood | Targeted anemia evaluation |
| Nutrient status | Vitamin B12, Folate, Vitamin D 25-Hydroxy, Magnesium, and Zinc | Blood | Risk-based deficiency testing |
| Initial celiac serology | Tissue Transglutaminase IgA with Total IgA | Blood | Preferred starting strategy for most patients |
| Additional celiac serology | Endomysial IgA, DGP IgG and IgA, and tTG-IgG | Blood | Selected or reflex testing |
| Celiac genetic compatibility | HLA Typing for Celiac Disease | Blood or laboratory-specified specimen | Selected exclusion-oriented use |
| Intestinal inflammation | Calprotectin Stool Test and Lactoferrin Quantitative Stool Test | Stool | Targeted inflammatory assessment |
| Occult colorectal bleeding screening | FIT Test and Fecal Globin by Immunochemistry | Stool | Screening in eligible adults without symptoms |
| Active H. pylori infection | H. pylori Stool Antigen and H. pylori Urea Breath Test | Stool or breath | Diagnosis support and appropriately timed test of cure |
| Infectious diarrhea | Gastrointestinal Pathogen Panel, Ova and Parasites Stool Examination, Salmonella/Shigella Culture, Campylobacter EIA, and Shiga Toxin with Reflex, and C. difficile Toxin B | Stool | Risk-based or targeted testing |
| Pancreatic exocrine output and fat malabsorption | Pancreatic Elastase-1 and Qualitative Fecal Fat | Stool | Targeted malabsorption evaluation |
| Acute pancreatic injury context | Lipase and Amylase | Blood | Targeted or acute-care testing—not routine screening |
| IBD differentiation markers | ASCA IgA, ASCA IgG, ANCA Screen with Reflex, and IBD Differentiation Panel | Blood | Specialist-directed adjuncts; not stand-alone diagnostic tests |
| Lactose-intolerance evaluation | Ulta Lactose-Intolerance Testing Category | Varies | Review current availability; do not substitute milk-allergy testing for lactose-malabsorption evaluation |
GI pathogen panel naming matters: the Gastrointestinal Pathogen Panel and the Gastrointestinal Pathogen Panel, Real-Time PCR are separate Ulta product candidates. Their targets, method, specimen rules, and reporting may differ. Review the live contents of the exact page ordered; do not treat the two names as interchangeable.
The digestive system includes the gastrointestinal tract—the mouth, esophagus, stomach, small intestine, large intestine, rectum, and anus—along with the liver, pancreas, and gallbladder. These organs move food, break it down, absorb nutrients and water, produce or store digestive fluids, and remove waste.1
Digestive health lab testing is not one test. It is a set of blood, stool, breath, and tissue-based methods chosen to answer different questions. Blood tests may reveal anemia, dehydration, electrolyte disturbance, systemic inflammation, liver-related patterns, pancreatic enzyme elevation, nutrient deficiency, or celiac-associated antibodies. Stool tests can look more directly for intestinal inflammation, hidden blood, pathogens, pancreatic enzyme output, or fat malabsorption. Breath tests may evaluate lactose malabsorption, selected carbohydrate intolerances, small-intestinal bacterial overgrowth in appropriate settings, or active H. pylori. Endoscopy and biopsy allow direct visualization and tissue sampling.
Symptoms alone are often insufficient because bloating, diarrhea, constipation, pain, nausea, fatigue, and altered stool can occur in inflammatory, infectious, structural, metabolic, medication-related, dietary, and disorders of gut-brain interaction. Objective testing can narrow possibilities, but it may still be insufficient without a medical history, physical examination, imaging, endoscopy, biopsy, or other functional testing.
Digestive symptoms can be brief and self-limited, but persistent or recurrent symptoms may affect hydration, nutrient absorption, blood counts, body weight, bone health, energy, and quality of life. Testing can help identify complications even when it cannot establish the underlying diagnosis.
A larger panel is not automatically more useful. The most informative approach starts with the patient’s question, symptom pattern, duration, risk factors, medicines, previous results, and the consequences of missing a serious condition or generating a false-positive result.
| Question | Examples of tests | What the results may reveal |
|---|---|---|
| Is there evidence of anemia or blood-cell disruption? | CBC, ferritin, iron and TIBC, reticulocytes when indicated | Anemia pattern, iron depletion, white-cell change, or platelet response that merits further evaluation |
| Is dehydration or metabolic disruption present? | CMP or selected electrolytes and kidney markers | Fluid, electrolyte, kidney, glucose, protein, bilirubin, or liver-enzyme abnormalities |
| Is there systemic or intestinal inflammation? | CRP, ESR, fecal calprotectin, fecal lactoferrin | A nonspecific systemic inflammatory signal or a more intestine-focused inflammatory signal |
| Is celiac disease a reasonable concern? | tTG-IgA, total IgA, selected EMA or DGP testing | An antibody pattern that supports gastroenterology follow-up and, in many adults, endoscopy with duodenal biopsies |
| Could infection be contributing? | Targeted stool culture, antigen, toxin, PCR, ova-and-parasite testing, H. pylori stool antigen or breath testing | Evidence of a selected pathogen or toxin, interpreted with symptoms and exposure history |
| Could pancreatic exocrine output be low? | Pancreatic elastase, selected fecal fat testing, nutrient tests | A pattern compatible with pancreatic insufficiency or fat malabsorption that requires confirmation and cause evaluation |
| Is occult colorectal bleeding detected during screening? | FIT or high-sensitivity guaiac stool testing in eligible, asymptomatic adults | Microscopic blood that requires follow-up colonoscopy when positive |
| Laboratory testing cannot reliably do this by itself | What may be needed instead or in addition |
|---|---|
| Show ulcers, polyps, tumors, strictures, diverticula, gallstones, bowel obstruction, or the exact location of bleeding | Endoscopy, colonoscopy, capsule endoscopy, ultrasound, CT, MRI, or other imaging |
| Confirm Crohn’s disease or ulcerative colitis from CRP, ESR, calprotectin, ASCA, or pANCA alone | Gastroenterology evaluation, endoscopy with biopsies, and imaging when appropriate |
| Diagnose irritable bowel syndrome with one blood or stool test | History-based symptom assessment, physical examination, limited rule-out testing, and evaluation of warning signs |
| Confirm adult celiac disease in every case from serology alone | Upper endoscopy with duodenal biopsies in many adults and selected other patients |
| Determine the cause of a low nutrient level | Dietary history, medication review, bleeding evaluation, malabsorption assessment, and sometimes endoscopy or imaging |
| Measure stomach emptying, intestinal transit, bile-acid diarrhea, or pelvic-floor function | Functional studies, gastric-emptying testing, breath tests, anorectal testing, or specialist-directed therapeutic trials |
| Rule out serious disease simply because a result is normal | Clinical reassessment and additional testing when symptoms, history, or examination remain concerning |
The examples below are educational. A symptom does not confirm a disease, and the same symptom may have several unrelated causes.
| Symptom, risk factor, medication, or life stage | Possible explanations | Laboratory tests that may add information | Nonlaboratory evaluation that may be needed | Safety or urgency note |
|---|---|---|---|---|
| Persistent diarrhea | Infection, celiac disease, IBD, medication effect, microscopic colitis, malabsorption, pancreatic insufficiency, lactose intolerance, or IBS-D | CBC, CMP, celiac serology, CRP, fecal calprotectin, and targeted stool pathogen tests | Medication and exposure review; endoscopy or imaging when indicated | Prompt care for blood, fever, severe pain, faintness, or dehydration |
| Bloating, gas, or bowel-pattern change without warning signs | Dietary fermentation, constipation, lactose intolerance, celiac disease, SIBO in selected contexts, or a disorder of gut-brain interaction | Focused celiac testing; other tests only when history supports them | History, examination, dietary assessment, and selected breath testing | Unexplained weight loss, anemia, bleeding, nocturnal symptoms, or progressive pain requires evaluation |
| Upper abdominal burning, ulcer history, or unexplained iron deficiency | H. pylori, ulcer disease, medication injury, reflux, gastritis, or another upper-GI disorder | H. pylori stool antigen or urea breath test; CBC and iron studies when bleeding is possible | Upper endoscopy when alarm features or persistent symptoms are present | Black stool, bloody vomit, dizziness, or sudden severe pain needs urgent care |
| Blood in stool or black, tarry stool | Hemorrhoids, fissure, ulcer, diverticular bleeding, IBD, polyps, cancer, medication-related bleeding, or another source | CBC and selected coagulation or metabolic tests; FIT is not a substitute for diagnostic evaluation of visible bleeding | Prompt clinical examination, endoscopy, colonoscopy, or imaging | Urgent or emergency evaluation may be required |
| Greasy or difficult-to-flush stool, weight loss, or fat-soluble vitamin deficiency | Exocrine pancreatic insufficiency, celiac disease, small-bowel disease, bile-flow problems, or another malabsorptive disorder | Pancreatic elastase, selected fecal fat testing, CBC, CMP, iron, B12, folate, vitamin D, and celiac testing | Pancreatic or biliary imaging, endoscopy, and specialist evaluation | Rapid weight loss, jaundice, or severe pain warrants prompt assessment |
| Fatigue with anemia or low iron | Dietary deficiency, menstrual or GI blood loss, celiac disease, IBD, reduced absorption, or chronic inflammation | CBC, ferritin, iron and TIBC, B12, folate, CRP, and celiac serology when appropriate | Bleeding history, dietary review, gynecologic evaluation, endoscopy, or colonoscopy depending on context | Chest pain, fainting, marked shortness of breath, or rapidly worsening weakness needs prompt care |
| Right-upper-quadrant pain, dark urine, pale stool, or jaundice | Gallstone or bile-duct obstruction, hepatitis, medication injury, pancreatic disease, or another hepatobiliary condition | CMP or focused liver tests; CBC; lipase when pancreatitis is suspected | Ultrasound or other urgent imaging | Jaundice with fever or significant pain may be an emergency |
| Severe upper abdominal pain radiating to the back with vomiting | Acute pancreatitis, gallbladder disease, ulcer complication, vascular emergency, or another acute abdominal condition | Lipase and selected acute-care blood tests | Immediate examination and imaging as clinically indicated | Do not delay urgent evaluation for a routine outpatient lab order |
| Diarrhea during or after antibiotics or healthcare exposure | C. difficile, another infection, medication effect, or underlying bowel disease | Appropriate C. difficile testing on diarrheal stool and other targeted stool tests | Clinical evaluation, hydration assessment, and treatment guidance | Fever, severe pain, blood, confusion, or dehydration needs prompt care |
| Family history of celiac disease, IBD, colorectal cancer, or hereditary GI disease | Increased condition-specific risk | Risk-based celiac serology, CBC/iron tests, or other tests selected for the family condition | Earlier or specialized screening, colonoscopy, or genetic counseling | Screening plans should reflect the exact family history and age at diagnosis |
These tests are often used early when symptoms are persistent or when an abnormality such as anemia, dehydration, or weight loss needs context.
These tests are most useful when the symptom pattern, exposure, medical history, or a previous result creates a specific clinical question.
Monitoring is used to follow a known diagnosis, a prior abnormality, treatment response, or complications—not merely to repeat a broad panel on a fixed schedule.
Commercial microbiome “dysbiosis” scores, intestinal-permeability or “leaky gut” panels, broad food-IgG panels, generalized cytokine panels, and some direct-to-consumer metabolomic tests may be marketed for digestive symptoms. Their clinical validity, standardization, actionability, and ability to improve patient outcomes remain limited or inconsistent for routine care. An interesting result is not automatically a diagnosis or a treatment target.
These tables describe common clinical uses and limitations. “High,” “low,” “positive,” or “negative” has meaning only in relation to the laboratory method, specimen, reference information, patient context, and related results.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Complete Blood Count with Differential and Platelets CBC, CBC with differential, complete blood count First-line | Measures red blood cells, hemoglobin, hematocrit, red-cell indices, white blood cells, and platelets. It may be ordered to look for anemia patterns, infection-related changes, inflammation-associated findings, or complications of blood loss. Low hemoglobin can support an anemia pattern; white-cell and platelet changes are nonspecific and need clinical context. | Blood test; fasting is usually not needed when ordered alone. Hydration, pregnancy, altitude, recent illness, bleeding, medications, and laboratory method can affect results. A CBC cannot identify the cause or location of anemia, bleeding, inflammation, or infection by itself. |
| Comprehensive Metabolic Panel CMP, chemistry panel First-line | Measures selected electrolytes, kidney markers, glucose, calcium, proteins, bilirubin, and liver-associated enzymes. It may be ordered to assess dehydration, electrolyte disturbance, albumin, bilirubin, kidney context, and liver-related patterns. High or low values may reflect fluid balance, organ function, nutrition, medicines, or acute illness; the pattern matters more than one result. | Blood test; follow the order and laboratory instructions because fasting may be needed for accompanying tests. Hydration, recent exercise, alcohol, hemolysis, medicines, supplements, acute illness, and fasting status can affect results. A CMP cannot establish a specific bowel, gallbladder, bile-duct, liver, or pancreatic diagnosis by itself. |
| C-Reactive Protein CRP Targeted | Measures a liver-produced protein that rises with many inflammatory states. It may be ordered as a systemic inflammation marker and to provide context for possible inflammatory bowel disease, infection, or another inflammatory condition. A high result supports inflammation but does not identify the source; a normal result does not exclude localized intestinal disease. | Blood test; fasting is usually not needed when ordered alone. Recent infection, injury, surgery, inflammatory disease, pregnancy, obesity, and medicines can affect results. CRP cannot diagnose IBD, infection, or the location and cause of inflammation by itself. |
| Sedimentation Rate Blood Test ESR, sed rate Targeted | Measures how quickly red blood cells settle in a tube, an indirect marker influenced by inflammation and blood-cell characteristics. It may be ordered as another nonspecific inflammatory data point. A high result can occur with inflammation, anemia, pregnancy, age-related changes, kidney disease, or other conditions; a normal result does not rule out digestive disease. | Blood test; fasting is usually not needed when ordered alone. Anemia, red-cell shape, age, pregnancy, kidney disease, technical factors, and medicines can affect results. ESR cannot identify the cause, site, or severity of intestinal disease by itself. |
| Iron, TIBC, and Ferritin Panel Iron studies, iron panel, Fe, TIBC, transferrin saturation Targeted | Measures stored iron, circulating iron, binding capacity, and calculated iron availability. It may be ordered to evaluate iron depletion, anemia, chronic blood loss, inflammation, or malabsorption. Low ferritin commonly supports depleted iron stores, but ferritin may be normal or high during inflammation; the full iron pattern is more useful than serum iron alone. | Blood test; follow the laboratory’s fasting and timing instructions, and disclose supplements. Inflammation, recent iron intake, time of day, menstruation, bleeding, liver disease, and supplements can affect results. Iron studies cannot identify the source of blood loss or the reason iron is low by themselves. |
| Vitamin B12 and Folate Panel Test Cobalamin, B12, folic acid, folate Targeted; Monitoring when deficient | Measures circulating vitamin B12 and folate status. It may be ordered to investigate macrocytic anemia, neuropathy, dietary risk, gastric disease, medication effects, or small-bowel malabsorption. Low or borderline results may support deficiency but can require confirmatory markers or cause evaluation; high results may reflect supplementation or another condition. | Blood test; follow laboratory instructions and disclose supplements or recent injections. Supplements, injections, fortified foods, pregnancy, kidney or liver disease, and assay method can affect results. The test cannot show whether the cause is diet, pernicious anemia, celiac disease, medication use, or another malabsorptive disorder by itself. |
Primary clinical sources: MedlinePlus CBC, CMP, CRP, ESR, ferritin, and vitamin B12 testing.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Tissue Transglutaminase IgA Antibody Test tTG-IgA, TTG IgA First-line; Monitoring after diagnosis | Measures IgA antibodies directed against tissue transglutaminase. It is the preferred first-line serologic test for most people being evaluated for celiac disease.3, 4 A positive result raises suspicion for celiac disease; a negative result is less reassuring when gluten intake is low, IgA is deficient, disease is mild, or clinical suspicion remains high. | Blood test; the patient generally needs to be eating gluten for accurate serology. Gluten restriction, IgA deficiency, immunosuppression, age, intestinal damage, and assay method can affect results. tTG-IgA does not provide a definitive adult celiac diagnosis in every case by itself. |
| IgA Test Total IgA, quantitative IgA Targeted | Measures the total concentration of IgA, not a celiac-specific antibody. It may be ordered with initial celiac serology to determine whether IgA-based tests can be interpreted and to identify possible IgA deficiency. A low result can make tTG-IgA and EMA-IgA falsely negative and may prompt an IgG-based testing strategy. | Blood test; no special fasting in most cases. Immunodeficiency, some medicines, protein loss, liver disease, and laboratory method can affect results. Total IgA cannot diagnose celiac disease by itself. |
| Endomysial IgA Antibody Screen with Reflex to Titer EMA-IgA, endomysial antibody Targeted; Confirmatory serology | Measures IgA antibodies against endomysial targets, commonly by immunofluorescence. It may be used to increase serologic confidence after or alongside tTG-IgA in selected situations. A positive result strongly supports celiac-type autoimmunity in the right context; a negative result does not exclude disease when IgA is low or gluten intake is inadequate. | Blood test; continue medically appropriate gluten intake until diagnostic testing is complete. Gluten restriction, IgA deficiency, mild disease, reader interpretation, and method can affect results. EMA-IgA cannot determine whether endoscopy or biopsy is needed for an individual adult by itself. |
| Gliadin Deamidated Peptide IgA Antibody Test and Gliadin Deamidated Peptide IgG Antibody Test DGP-IgA, DGP-IgG Specialist-directed in selected contexts | Measures IgA or IgG antibodies to deamidated gliadin peptides. These tests may be useful with IgA deficiency, in some young children, or as part of a broader specialist-selected celiac strategy. A positive result may support celiac evaluation but is generally less preferred than tTG-IgA for most adults. | Blood test; testing should occur while consuming gluten unless a specialist directs otherwise. Gluten restriction, age, IgA status, other digestive disease, and assay method can affect results. DGP antibodies cannot diagnose celiac disease or non-celiac gluten sensitivity by themselves. |
| HLA Typing Test for Celiac Disease HLA-DQ2, HLA-DQ8, celiac HLA typing Targeted; Specialist-directed | Evaluates genetic variants strongly associated with celiac susceptibility. It may help exclude celiac disease in selected uncertain cases, including some people already eating gluten-free. Absence of relevant variants makes celiac disease very unlikely; presence is common and does not prove disease. | Blood or buccal specimen, depending on the laboratory; gluten exposure is not needed for genetic testing. Results do not change with diet, but interpretation depends on assay coverage and clinical context. HLA typing cannot show active celiac disease, intestinal injury, or the need for treatment by itself. |
Primary clinical source: NIDDK celiac disease testing guidance.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Calprotectin Stool Test Fecal calprotectin, stool calprotectin, FC Targeted; Monitoring | Measures calprotectin, a protein released mainly by activated neutrophils in the intestinal tract. It may help distinguish intestinal inflammation from a functional disorder and monitor selected patients with known IBD.7, 8, 9 Higher results support intestinal inflammation; lower results make active inflammation less likely in the right setting, but neither result is diagnostic by itself. | Stool test; no fasting, but collection and storage instructions should be followed exactly. GI infection, NSAID use, bleeding, age, collection quality, and laboratory method can affect results. It cannot determine whether inflammation is due to Crohn’s disease, ulcerative colitis, infection, cancer, celiac disease, or another cause by itself. |
| FIT Test Fecal immunochemical test, FIT, iFOBT Risk-based screening | Detects human hemoglobin from lower-GI bleeding. It is one guideline-supported colorectal-cancer screening option for eligible adults without symptoms. A positive result requires colonoscopy; a negative result does not rule out cancer or another bleeding source and must be repeated at the recommended interval when FIT is the chosen screening strategy. | Stool test; follow the kit instructions. FIT generally does not require dietary restriction. Intermittent bleeding, collection quality, delayed handling, and lesion location can affect results. FIT cannot identify the source of blood or diagnose colorectal cancer by itself. |
| Helicobacter pylori Antigen Stool Test H. pylori stool antigen, HpSA Targeted; Monitoring | Detects antigen from active H. pylori infection in stool. It may be ordered to evaluate active infection or confirm eradication after treatment.10 A positive result supports active infection; a negative result can be false if testing is done too soon after treatment or while interfering medicines are present. | Stool test; follow prescriber and laboratory medication and timing instructions. Proton-pump inhibitors, potassium-competitive acid blockers, antibiotics, bismuth, recent treatment, and sample handling can affect results. It cannot determine ulcer location, cancer, or the cause of all upper-GI symptoms by itself. |
| Helicobacter pylori Urea Breath Test UBT, carbon urea breath test Targeted; Monitoring | Measures urease activity consistent with active H. pylori infection. It may be ordered to detect active infection or document eradication after treatment. A positive result supports active infection; a negative result is less reliable if preparation or post-treatment timing is unsuitable. | Breath test; follow exact fasting, medication, and timing instructions. Acid suppressors, antibiotics, bismuth, food intake, recent treatment, and collection technique can affect results. It cannot show ulcer severity or determine whether endoscopy is needed when alarm features are present. |
| Gastrointestinal Pathogen Panel, Real-Time PCR, Ova and Parasites Stool Test, and Salmonella/Shigella Culture, Campylobacter EIA, and Shiga Toxin with Reflex Stool PCR, multiplex GI panel, culture, ova and parasite exam, antigen, toxin assay Targeted | Detects selected microbial DNA or RNA, antigen, toxin, viable organisms, or parasites depending on the method. These tests may be ordered for diarrhea with relevant severity, duration, fever, blood, exposure, travel, immune status, outbreak concern, or public-health implications.11, 12 A detected target may identify a likely pathogen, but molecular detection can reflect nonviable organisms or colonization, and more than one target may be detected. | Diarrheal stool or stool specimen, depending on the test; collect the correct specimen promptly and follow storage and transport instructions. Antibiotics, collection timing, formed versus diarrheal stool, transport, contamination, and method can affect results. Detection does not prove the organism is causing every symptom or that treatment is appropriate. |
| Clostridium difficile Toxin B Qualitative Test C. difficile, C. diff, NAAT, PCR, toxin test Targeted | Detects toxigenic-organism genes and/or toxin depending on the testing algorithm. It may be ordered for compatible new-onset diarrhea, especially with antibiotic or healthcare exposure. A positive molecular result can occur with colonization; toxin findings and clinical context help determine whether disease is likely. | Unformed stool test; test only an appropriate diarrheal specimen unless a clinician directs otherwise. Testing formed stool, laxative use, colonization, specimen handling, and the testing algorithm can affect interpretation. A molecular result alone cannot establish active infection. |
| Pancreatic Elastase-1 Test Fecal elastase, FE-1 Targeted | Measures the concentration of a pancreatic enzyme that remains stable during intestinal transit. It is often used as an initial test when exocrine pancreatic insufficiency is suspected. A low result supports reduced pancreatic exocrine output when consistent with symptoms; borderline results may require repeat or additional evaluation. | Stool test; use a formed or semiformed specimen when possible and follow storage instructions. Watery stool dilution, sample quality, mild disease, and low pretest probability can affect results. It cannot identify the cause of insufficiency, pancreatic anatomy, or acute pancreatitis by itself. |
| Fecal Fat, Qualitative Stool Test Qualitative fecal fat, Sudan stain; quantitative fecal fat Specialist-directed | Evaluates excess fat in stool. It may be ordered when steatorrhea, weight loss, or fat-soluble vitamin deficiency raises concern for fat malabsorption. An abnormal result supports fat malabsorption but does not identify whether the cause is pancreatic, biliary, or small-intestinal. | Stool test; requirements differ substantially between qualitative and timed quantitative tests. Dietary fat intake, incomplete timed collection, medicines, laxatives, contamination, and method can affect results. It cannot identify the cause or location of malabsorption by itself. |
| Lactose Hydrogen Breath Test Hydrogen breath test, lactose malabsorption breath test Targeted | Measures hydrogen in exhaled breath after a measured lactose load. It may be used to evaluate incomplete lactose digestion and fermentation. A rise in breath hydrogen with compatible symptoms supports lactose malabsorption, but symptoms and test results may not always match. | Breath test; follow the testing center’s exact diet, fasting, smoking, exercise, and medication instructions. Recent antibiotics, bowel preparation, smoking, exercise, diet, bacterial gas-production pattern, and SIBO can affect results. It cannot diagnose milk allergy, explain every symptom, or determine whether all dairy must be avoided by itself. |
| Lipase Test and Amylase Test Pancreatic enzymes Targeted; acute-care context | Measure circulating digestive enzymes, with lipase generally more useful for suspected acute pancreatitis. They may support evaluation when symptoms are compatible with acute pancreatic injury. Marked enzyme elevation may support pancreatic injury, but elevations can occur for other reasons; normal values do not address every pancreatic disorder. | Blood tests; severe acute pain and vomiting require prompt clinical evaluation rather than delayed routine testing. Timing from symptom onset, kidney function, medicines, salivary disease, macroenzymes, and assay method can affect results. Lipase and amylase cannot establish acute pancreatitis without compatible symptoms and/or imaging, and they do not diagnose chronic pancreatitis or exocrine insufficiency by themselves. |
Primary clinical sources: MedlinePlus calprotectin stool test; USPSTF colorectal cancer screening; ACG H. pylori and acute pancreatitis guidance; IDSA infectious diarrhea guidance; CDC C. difficile laboratory testing; AGA exocrine pancreatic insufficiency guidance; NIDDK exocrine pancreatic insufficiency and lactose intolerance diagnosis guidance.
Educational framework—not a diagnostic or treatment algorithm.
| Method | Best suited to reveal | Examples | Advantages | Limitations | When another method may be needed |
|---|---|---|---|---|---|
| Blood testing | Whole-body effects, immune response, anemia, inflammation, dehydration, nutrients, liver or pancreatic-enzyme patterns | CBC, CMP, CRP, ESR, iron studies, B12, folate, celiac serology, lipase | Familiar collection; can evaluate several systemic complications at once | Often indirect and nonspecific; cannot visualize tissue or localize disease | Use stool testing, imaging, endoscopy, or biopsy when the question is intestinal inflammation, infection, bleeding source, anatomy, or tissue diagnosis |
| Stool testing | Signals originating in or passing through the intestinal tract | Calprotectin, pathogen tests, FIT, pancreatic elastase, fecal fat | More organ-proximal for intestinal inflammation, bleeding, pathogens, and pancreatic exocrine output | Collection and handling matter; one sample may miss intermittent findings; positive results may still be nonspecific | Use endoscopy, imaging, or repeat/targeted testing when a positive result requires localization or confirmation |
| Breath testing | Microbial gas production or urease activity after a test substrate | Lactose hydrogen breath test, selected SIBO tests, H. pylori urea breath test | Noninvasive and function-focused | Preparation-sensitive; false positives and negatives occur; not every positive result explains symptoms | Use endoscopy, stool testing, imaging, or dietary assessment when warning signs, alternative diagnoses, or structural disease are possible |
| Endoscopy and biopsy | Direct visualization and microscopic tissue changes | Upper endoscopy, colonoscopy, duodenal biopsy, gastric biopsy, intestinal biopsy | Can identify and sample ulcers, polyps, inflammation, tumors, villous injury, and microscopic disease | Invasive; requires preparation; carries procedural and sedation risks; samples only examined areas | Use imaging for areas outside reach, capsule studies for selected small-bowel questions, and lab testing for systemic effects or longitudinal monitoring |
| Test | Main question | Typical role | When it is especially useful | Important limitation | Does gluten intake matter? |
|---|---|---|---|---|---|
| tTG-IgA | Are celiac-associated IgA autoantibodies present? | Preferred initial serology for most patients | Symptoms, iron deficiency, osteoporosis risk, autoimmune association, or family history | Can be falsely negative with IgA deficiency, reduced gluten exposure, or mild disease | Yes |
| Total IgA | Is the patient able to produce enough IgA for IgA-based celiac tests to be reliable? | Interpretive companion to tTG-IgA | Initial testing or negative IgA serology despite meaningful suspicion | It is not a celiac-specific antibody | No for the IgA concentration itself, but the celiac antibody tests still require gluten exposure |
| EMA-IgA | Can a highly specific second IgA antibody increase confidence? | Selected confirmatory serology | Clarifying a positive or strongly positive tTG-IgA pattern | More technique- and reader-dependent; affected by IgA deficiency and gluten restriction | Yes |
| DGP-IgG or tTG-IgG | Can an IgG-based strategy help when IgA is deficient? | Selected alternative serology | Confirmed IgA deficiency and selected pediatric or specialist contexts | IgG tests are not interchangeable with tTG-IgA in IgA-sufficient adults | Yes |
| HLA-DQ2/DQ8 | Is the genetic background compatible with celiac disease? | Exclusion tool in uncertain cases | Already gluten-free, discordant serology/biopsy, or uncertain historical diagnosis | A positive result is common and does not diagnose celiac disease | No |
| Upper endoscopy with duodenal biopsies | Is there characteristic small-intestinal tissue injury? | Diagnostic confirmation in many adults | Positive serology, high clinical suspicion, or unresolved discordance | Sampling and pathology interpretation matter; prior gluten restriction can reduce yield | Yes, in most diagnostic pathways |
Celiac antibody levels and small-intestinal injury can decline after gluten is removed. Starting a gluten-free diet before blood testing or biopsy may therefore produce a false-negative or less conclusive result. That can make it harder to distinguish celiac disease from wheat allergy, non-celiac gluten sensitivity, IBS, or another cause of symptoms.
A person who has already stopped gluten should not deliberately restart it without discussing the risks and the diagnostic plan with a qualified clinician. The next step may involve review of prior records, HLA testing, a professionally supervised gluten challenge, repeat serology, or endoscopy. The safest and most informative approach depends on symptoms, nutritional status, pregnancy, age, and the possibility of a severe reaction or another diagnosis.
| Feature | Inflammatory condition pattern | Functional or disorder-of-gut-brain-interaction pattern | Useful tests or evaluation | Key caution |
|---|---|---|---|---|
| Examples | Crohn’s disease, ulcerative colitis, some infections, celiac disease, microscopic colitis | Irritable bowel syndrome and functional bloating | History, examination, targeted labs, stool markers, endoscopy when indicated | A patient can have more than one condition |
| Tissue injury | May produce visible, microscopic, biochemical, or imaging evidence of inflammation | Symptoms arise without the same pattern of destructive inflammation on routine testing | Fecal calprotectin, CRP, endoscopy, biopsy, imaging | A normal marker does not exclude every inflammatory disorder |
| Common clues | Blood in stool, nocturnal diarrhea, fever, weight loss, anemia, high calprotectin, growth problems, family history | Recurrent abdominal pain related to defecation plus altered stool frequency or form, often without alarm features | Use limited rule-out testing based on subtype and risk | Symptoms alone do not establish either category |
| Role of CRP/ESR | May be elevated but can be normal despite intestinal inflammation | Usually not elevated because of IBS itself | CRP may be paired with fecal calprotectin in selected diarrhea-predominant presentations | These are nonspecific markers |
| Role of fecal calprotectin | Often elevated with active neutrophilic intestinal inflammation | Usually low when no intestinal inflammation is present | Useful to help decide whether endoscopic assessment is more likely to be needed | Infection, medicines, age, and other diseases can elevate it |
| Can one blood test diagnose IBS? | Not applicable | No | IBS is assessed from a characteristic symptom pattern after appropriate evaluation of warning signs and selected alternatives | Broad “IBS blood panels” should not replace clinical assessment |
| Testing option | Typical contents or focus | When it may be useful | Advantages | Limitations | Risk of incidental findings | Questions to ask before ordering |
|---|---|---|---|---|---|---|
| Single test | One defined biomarker, such as tTG-IgA, calprotectin, lipase, FIT, or pancreatic elastase | When there is one clear clinical question and the needed companion tests are understood | Focused, easier to interpret, and less likely to produce unrelated abnormalities | May be incomplete when interpretation requires a companion test—for example, tTG-IgA without total IgA in a person with possible IgA deficiency | Low to moderate | Does this test answer the question by itself? Is a companion or confirmatory test needed? |
| Small, purpose-built panel | Related tests such as tTG-IgA plus total IgA, or ferritin with iron/TIBC | When the components jointly answer a defined diagnostic-support or monitoring question | May reduce missed context and simplify ordering | Panel contents and reflex rules vary; every component may not be needed | Moderate | What exactly is included? Are reflex tests automatic? Would the result change next steps? |
| Broad symptom panel | Multiple blood, nutrient, inflammatory, liver, pancreatic, or antibody tests | Only when each component maps to the symptom pattern and there is a follow-up plan | Can assess several plausible complications at once | May still miss the correct stool, breath, imaging, or endoscopic test; can generate unrelated abnormalities | Moderate to high | Which components are necessary? What is the plan for borderline or unrelated results? |
| Multiplex stool pathogen panel | Multiple bacterial, viral, and parasitic targets detected by molecular methods | Selected severe, prolonged, immunocompromised, outbreak, or public-health contexts | Fast, broad organism detection from one specimen | Can detect colonization, nonviable organisms, or multiple targets; may not include susceptibility information | Moderate to high | Is infectious testing indicated? Would a targeted test be more appropriate? How will multiple detections be interpreted? |
| Commercial microbiome or food-sensitivity panel | Microbial abundance, “dysbiosis” scores, food IgG, permeability markers, or proprietary composite scores | Generally not recommended for routine diagnosis of common digestive symptoms | May generate exploratory information | Limited standardization, uncertain clinical utility, and risk of unnecessary dietary restriction or treatment | High | Is the method clinically validated? Is there guideline support? Will the result improve outcomes? |
Panel verification note: Exact Ulta Lab Tests panel names, components, reflex rules, specimen requirements, and availability must be rechecked on the live product page immediately before publication.
| Common name | Abbreviation or alias | What the name refers to | Do not confuse it with |
|---|---|---|---|
| Complete blood count | CBC; CBC with differential | Blood-cell counts and indices | A blood smear or iron studies, which answer different questions |
| Comprehensive metabolic panel | CMP | A group of metabolic, kidney, protein, bilirubin, and liver-associated measurements | A digestive “comprehensive panel,” which may have different contents |
| C-reactive protein | CRP | A nonspecific systemic inflammation marker | High-sensitivity CRP, which is commonly used for cardiovascular-risk assessment |
| Erythrocyte sedimentation rate | ESR; sed rate | An indirect inflammation marker based on red-cell settling | CRP; the two tests behave differently and are not interchangeable |
| Tissue transglutaminase IgA | tTG-IgA; TTG IgA | The preferred initial celiac-associated antibody for most patients | Total IgA, which checks IgA quantity rather than celiac autoimmunity |
| Endomysial antibody | EMA-IgA | A highly specific celiac-associated IgA antibody | Deamidated gliadin peptide antibodies |
| Deamidated gliadin peptide | DGP-IgA; DGP-IgG | Selected celiac-associated antibodies | Older native antigliadin antibody tests |
| Fecal calprotectin | FC; stool calprotectin | An intestinal inflammation marker | Serum calcium or calcitonin |
| Fecal immunochemical test | FIT; iFOBT | A stool test for human hemoglobin used in colorectal screening | Guaiac fecal occult blood testing, which uses a different chemical method |
| Fecal occult blood test | FOBT; gFOBT | A broad term often used for guaiac-based occult blood testing | Evaluation of visible rectal bleeding or black stool |
| Gastrointestinal pathogen panel | GI PCR panel; multiplex GI panel | A molecular panel detecting selected pathogen targets | A stool culture, which detects viable organisms and may allow susceptibility testing |
| Clostridioides difficile | C. difficile; C. diff | A bacterium evaluated with toxin and/or molecular methods | A positive molecular result alone, which may represent colonization |
| Pancreatic elastase-1 | FE-1; fecal elastase | A stool marker of pancreatic exocrine output | Serum elastase or lipase |
| Exocrine pancreatic insufficiency | EPI | Inadequate delivery of pancreatic digestive enzymes to the intestine | Acute pancreatitis, which is a different clinical condition |
| Urea breath test | UBT | A breath test for active H. pylori urease activity | Hydrogen breath testing for lactose malabsorption or SIBO |
| Small-intestinal bacterial overgrowth | SIBO | A clinical syndrome sometimes evaluated with glucose or lactulose breath testing | A general stool microbiome profile |
Preparation instructions vary by test, laboratory method, medicine, and collection kit. Never stop a prescription or nonprescription medicine solely because of general online guidance. Confirm the plan with the prescribing professional and the performing laboratory.
| Factor | Tests commonly affected | How the factor may alter results | General preparation guidance | Important caution |
|---|---|---|---|---|
| Gluten restriction | tTG-IgA, EMA-IgA, DGP antibodies, duodenal biopsy | Antibody concentrations and intestinal injury may decline, causing false-negative or less conclusive testing | Complete the diagnostic plan while eating a medically appropriate gluten-containing diet unless a qualified clinician directs otherwise | Do not restart gluten on your own after a severe reaction or after prolonged avoidance |
| Low total IgA | tTG-IgA and EMA-IgA | IgA-based celiac tests may be falsely negative | Pair initial celiac serology with total IgA when appropriate; use an IgG-based strategy under professional guidance if IgA deficiency is present | Total IgA is an interpretive companion, not a stand-alone celiac test |
| Fasting | CMP when bundled with glucose or lipids; iron studies in some laboratories; urea breath testing; carbohydrate breath tests | Food may alter glucose, triglycerides, iron, and breath-test substrate handling | Follow the exact instructions for the entire order, not just one component | People with diabetes, pregnancy, frailty, or a history of hypoglycemia should discuss fasting safety |
| Hydration | CBC, CMP, kidney markers, proteins | Dehydration may concentrate some blood values; excess fluid can dilute them | Maintain usual hydration unless specifically instructed otherwise | Persistent vomiting or inability to keep fluids down requires clinical assessment |
| Proton-pump inhibitor or potassium-competitive acid blocker | H. pylori stool antigen and urea breath testing | May suppress bacterial activity and cause a false-negative result | Obtain test-specific instructions from the clinician and laboratory; an appropriate temporary hold may be required | Do not stop prescribed acid suppression without guidance, especially with ulcer, bleeding, or severe reflux history |
| Antibiotics or bismuth | H. pylori tests, stool culture, molecular pathogen tests, breath tests | May suppress organisms or alter intestinal flora and test performance | Report recent use and follow the required post-treatment waiting period | H. pylori eradication testing is generally delayed until at least four weeks after antibiotics |
| NSAIDs | Fecal calprotectin, occult blood testing, CBC | May contribute to mucosal injury, bleeding, or higher calprotectin | Record the medicine, dose, and timing for interpretation | Do not stop prescribed antiplatelet or pain therapy without professional guidance |
| Watery stool | Pancreatic elastase | Dilution can produce a falsely low concentration | Use solid or semisolid stool when possible and follow collection instructions | A low result from a watery specimen may need confirmation rather than immediate labeling as pancreatic insufficiency |
| Formed stool | C. difficile testing | Testing people without compatible diarrhea increases detection of colonization | Submit an unformed specimen only when testing criteria are met, unless a clinician directs otherwise | A positive molecular test does not always mean symptomatic infection |
| Collection contamination | Pathogen tests, calprotectin, FIT, fecal fat, elastase | Urine, toilet water, cleaning chemicals, or mixed specimens may invalidate or distort results | Use the supplied collection device and follow the kit’s transfer, labeling, storage, and shipping directions | Contact the laboratory rather than submitting a visibly contaminated sample |
| Delayed transport or incorrect temperature | Stool culture, toxin assays, pathogen panels, calprotectin, elastase | Organisms, toxins, proteins, or nucleic acids may degrade or overgrow | Observe the collection kit’s time and temperature requirements | Requirements differ by preservative and assay |
| Recent bowel preparation or colonoscopy | Stool microbiology, calprotectin, breath tests, fecal fat | May change the microbiota, dilute stool, or temporarily alter bowel function | Ask how long to wait before collecting a routine specimen | Do not delay urgent evaluation for a suspected complication |
| Smoking, exercise, and diet before breath testing | Lactose, glucose, or lactulose hydrogen/methane tests | Can change breath-gas production or sample quality | Follow the test center’s pretest diet, fasting, smoking, exercise, and oral-hygiene rules | Protocols are not interchangeable between centers |
| Recent acute illness | CRP, ESR, ferritin, CBC, CMP, calprotectin | May create transient inflammatory, blood-count, metabolic, or intestinal changes | Tell the interpreting professional about fever, infection, surgery, injury, and symptom timing | Acute illness may be the reason to test immediately; do not postpone indicated care merely to obtain a “baseline” |
| Iron, B12, folate, biotin, or other supplements | Nutrient tests and selected immunoassays | Recent intake may raise measured concentrations or interfere with some laboratory methods | Disclose product, dose, and last use; follow laboratory instructions | Do not stop a medically necessary supplement without guidance |
| Prescription and nonprescription medicines | Nearly all groups, depending on drug and method | May cause symptoms, alter absorption, affect liver or kidney markers, suppress inflammation, or interfere analytically | Provide a complete medication list and ask whether timing affects collection | Never change therapy based solely on this article |
Start with the complete report: test name, specimen, method when shown, value, unit, reference information, flags, collection time, and related tests. Then add the patient context—symptoms, duration, preparation, medicines, diet, recent illness, previous values, and the reason the test was ordered.
Use the guide to reading and understanding laboratory results for a broader explanation of flags, units, ranges, thresholds, and trends.
| Term | What it means | How it is established | How it is used | Why it may differ | Patient caution |
|---|---|---|---|---|---|
| Laboratory reference interval | A statistical interval for a defined reference population | Laboratory validation, manufacturer data, or published reference studies | Flags results that fall outside the stated interval | Population, method, specimen, age, sex, and laboratory practices differ | An in-range value does not guarantee health; an out-of-range value does not establish disease |
| Diagnostic threshold | A value or pattern that contributes to a disease definition | Clinical studies and professional guidelines | Combined with symptoms, history, examination, imaging, pathology, or other tests | Guidelines and patient populations may differ | Many digestive diagnoses cannot be made from one laboratory threshold |
| Screening cutoff | A boundary designed to select people for additional evaluation | Balance of sensitivity, specificity, disease prevalence, harms, and benefits | Determines whether a confirmatory procedure is recommended | Screening program and test method differ | A positive FIT is a signal for colonoscopy, not a cancer diagnosis |
| Monitoring target | A goal used to follow a known disorder or treatment response | Guidelines, outcome studies, and individualized clinical judgment | Tracks change over time and helps decide whether evaluation should be adjusted | Disease phenotype, therapy, risk, and assay differ | Do not change medicine or diet from a single monitoring result without guidance |
| Qualitative interpretation | Positive, negative, detected, not detected, reactive, or nonreactive | Assay-specific signal rules and validation | Reports whether the target crosses the method’s decision rule | Targets, methods, and limits of detection differ | “Detected” does not always mean the target is causing symptoms |
Educational example only. The values and report flags below are fictional and do not provide universal reference ranges or diagnose a real person.
A fictional adult reports several months of loose stool, fatigue, and unintentional weight loss. The person was eating gluten at the time of testing and had not recently used antibiotics. A clinician ordered a CBC, ferritin and iron studies, tTG-IgA with total IgA, CRP, and fecal calprotectin.
| Test | Fictional result | Sample laboratory flag | Related result or context | What the pattern may suggest | What it does not prove |
|---|---|---|---|---|---|
| Hemoglobin | Below the sample laboratory’s stated interval | Low | MCV also below the interval | A microcytic anemia pattern that makes iron status and blood loss important questions | The cause or source of anemia |
| Ferritin | Below the sample laboratory’s stated interval | Low | Transferrin saturation also low | Depleted iron stores are likely in this fictional pattern | Whether iron loss is dietary, menstrual, gastrointestinal, or malabsorptive |
| tTG-IgA | Positive by the sample laboratory’s method | Positive | Total IgA is within the sample laboratory’s interval; gluten was being consumed | The IgA result is interpretable and the antibody pattern supports celiac evaluation | Celiac disease without appropriate professional assessment and, in many adults, duodenal biopsies |
| CRP | Within the sample laboratory’s stated interval | Not flagged | Fecal calprotectin is elevated | No strong systemic CRP signal at that moment | The absence of intestinal inflammation |
| Fecal calprotectin | Above the sample laboratory’s decision information | High | Persistent diarrhea and weight loss | An intestinal inflammatory signal that merits further evaluation | Whether the cause is celiac disease, IBD, infection, medicine-related injury, or another disorder |
The key lesson is that related results can strengthen or weaken a hypothesis without turning a laboratory pattern into a complete diagnosis. The warning features in this fictional scenario make professional evaluation more important than simply repeating a broad panel.
| Initial finding | Why follow-up may be needed | Possible next step |
|---|---|---|
| Positive celiac serology | Serology supports but may not complete the diagnosis | Gastroenterology review and, in many adults, upper endoscopy with duodenal biopsies while gluten is still being consumed |
| Negative tTG-IgA with low total IgA | The IgA test may be falsely negative | IgG-based celiac serology and professional evaluation |
| Negative celiac serology with high clinical suspicion | Reduced gluten intake, mild disease, IgA status, or seronegative celiac disease may complicate interpretation | Review diet and assay strategy; consider endoscopy or HLA testing in selected cases |
| Positive FIT | The test detects blood but cannot identify its source | Diagnostic colonoscopy rather than repeating FIT to “see if it goes away” |
| Borderline or elevated fecal calprotectin | Infection, NSAIDs, age, method, and transient inflammation may affect the result | Clinical review, selected pathogen testing, repeat testing, endoscopy, or imaging depending on the level and symptoms |
| Low fecal elastase from watery stool | Dilution can create a falsely low concentration | Repeat on a formed specimen and assess symptoms, nutritional status, and pancreatic imaging when appropriate |
| Positive H. pylori test after treatment | Persistent infection or unsuitable timing may need clarification | Review adherence and timing with a clinician; use an appropriately timed active-infection test |
| Negative H. pylori result while using interfering medicines | Suppression can cause a false negative | Repeat at an appropriate time under medication guidance if suspicion remains |
| Detected organism on a multiplex stool panel | Detection may represent colonization, residual nucleic acid, or coinfection | Clinical correlation, public-health reporting, culture, susceptibility testing, or no further testing depending on organism and symptoms |
| Unexpected nutrient deficiency | The result may be real but the cause is unresolved | Confirm when indicated and investigate diet, medicines, blood loss, celiac disease, gastric disease, pancreatic insufficiency, or other malabsorption |
Seek prompt professional evaluation for persistent or worsening digestive symptoms, unexplained anemia, recurrent nighttime symptoms, meaningful unintentional weight loss, fever, a new abdominal mass, progressive swallowing difficulty, recurrent vomiting, or symptoms beginning at an older age without a clear explanation.
Urgent or emergency evaluation may be necessary for:
Direct-access laboratory testing is not an emergency service and should not delay examination, imaging, endoscopy, intravenous fluids, or other urgent treatment.
| Article | What it covers | Question answered | Status |
|---|---|---|---|
| How Digestive Symptoms Can Affect Whole-Body Health | Connections among digestive symptoms, blood counts, nutrient status, inflammation, and other body systems | Why can a digestive problem produce symptoms outside the GI tract? | Retain and update |
| Nutrient Absorption and Digestive Disorders | Iron, B12, folate, vitamin D, protein, and other markers that may reveal complications of malabsorption | Which blood tests can reveal nutrient-absorption problems? | Retain and update |
| Nutrient Deficiencies Linked to Celiac Disease | Common deficiency patterns and why follow-up testing may be needed | Which nutrients may be low before or after a celiac diagnosis? | Retain and update |
| Celiac Disease, Wheat Allergy, and Non-Celiac Gluten Sensitivity Testing | How celiac serology, wheat-allergy evaluation, biopsy, genetics, and clinical assessment differ | What does “gluten intolerance testing” actually mean? | Retitle and substantially update |
| Inflammatory Bowel Disease Testing Beyond Symptoms | Calprotectin, CRP, CBC, nutrients, stool pathogens, endoscopy, imaging, and monitoring | How are Crohn’s disease and ulcerative colitis evaluated and monitored? | Retain and update |
| IBS Testing: What Labs Can and Cannot Rule Out | A limited, symptom-directed rule-out strategy and the role of warning signs | Is there a blood or stool test that diagnoses IBS? | Major rewrite |
| Lactose Intolerance and Hydrogen Breath Testing | Lactose malabsorption, breath-test preparation, symptom correlation, and alternatives | How is lactose intolerance evaluated? | Major rewrite |
| Pancreatitis: Lipase, Imaging, Causes, and Urgent Symptoms | Acute pancreatic injury and why routine enzyme screening is inappropriate | When do lipase and amylase help evaluate pancreatitis? | Major rewrite; separate pancreatic-cancer intent |
| Digestive Health After Gallbladder Removal | Post-cholecystectomy symptoms, nutrition, and when liver or pancreatic testing may be useful | Which symptoms and tests matter after gallbladder removal? | Reposition and update |
| Blood Tests for Inflammation | CRP, ESR, blood counts, and the limits of nonspecific inflammatory markers | What can inflammation blood tests reveal? | Assign primary parent to the inflammation pillar or narrow to digestive use |
| H. pylori Testing: Stool, Breath, and Biopsy | Active-infection tests, medication interference, test of cure, and endoscopy indications | Which H. pylori test is appropriate before and after treatment? | Proposed—create and verify URL |
| Stool Tests: Calprotectin, Infection, FIT, and Elastase | How collection, specimen consistency, purpose, and follow-up differ across stool tests | Which stool test answers which digestive question? | Proposed—create and verify URL |
| Pancreatic Insufficiency and Fecal Elastase Testing | Steatorrhea, pancreatic elastase, fecal fat, nutrient complications, and imaging | How is exocrine pancreatic insufficiency evaluated? | Proposed—create and verify URL |
| Gallbladder and Bile-Duct Tests: Blood Work and Imaging | Bilirubin and liver-enzyme patterns, pancreatic overlap, ultrasound, and urgent warning signs | Which tests help evaluate gallbladder or bile-duct concerns? | Proposed—create and verify URL |
Breath-test availability note: The article discusses lactose and SIBO breath testing because these methods are clinically relevant. A current direct Ulta product page for those breath tests was not confirmed during this update, so the article links to the Ulta lactose-intolerance testing category rather than inventing a product URL.
Use the smallest group of tests that answers a defined question. Each link below opens the corresponding Ulta Lab Tests page so that the current specimen, preparation, components, reflex rules, and availability can be reviewed before ordering.
Where available and after applicable eligibility requirements are met, Ulta Lab Tests allows patients to review available laboratory tests and posted pricing online, place an order, print the laboratory requisition, complete specimen collection at a participating patient service center, and review laboratory results through an online account. Availability, collection method, preparation, and timing vary by test and location.
Direct-access testing may help a patient gather objective information for a more informed conversation with a qualified healthcare professional. It does not replace examination, diagnosis, endoscopy, imaging, biopsy, emergency care, or treatment guidance. The direct-access laboratory testing guide explains the ordering, preparation, collection, result-delivery, and follow-up process.
A CBC and CMP are common starting tests when anemia, infection-related changes, dehydration, electrolyte disturbance, low albumin, bilirubin, or liver-associated abnormalities are possible. CRP or ESR, iron studies, celiac serology, and selected nutrient tests are added when the history supports them. Blood tests do not directly visualize the digestive tract.
No. There is no single blood test that confirms IBS. Clinicians identify a characteristic symptom pattern, check for warning signs, and use limited tests—such as celiac serology and, in selected patients with diarrhea, CRP and fecal calprotectin—to evaluate plausible alternatives.
For most patients, tTG-IgA is the preferred initial antibody test, usually interpreted with total IgA. IgG-based tests may be used when IgA deficiency is present or in selected specialist-directed contexts. Testing is most accurate while the patient is eating gluten.
Very low IgA can make an IgA-based celiac antibody test falsely negative. Total IgA shows whether tTG-IgA and EMA-IgA are likely to be interpretable and whether an IgG-based strategy may be needed.
Do not begin a gluten-free diet before completing celiac testing without professional guidance. Antibodies and intestinal injury may decline after gluten removal, making blood tests and biopsy less conclusive. A person already gluten-free should discuss HLA testing, prior records, or a supervised diagnostic plan rather than restarting gluten independently.
It raises suspicion but does not complete every adult diagnosis. The antibody level, total IgA, symptoms, gluten exposure, laboratory method, and related results matter. Many adults need upper endoscopy with duodenal biopsies for confirmation.
It measures a stool protein associated with intestinal neutrophilic inflammation. A high result can occur with IBD, infection, medicine-related injury, and other conditions. It helps assess whether an inflammatory process is likely but does not identify the cause by itself.
No. FIT is principally a colorectal-screening test for eligible people without symptoms.17 Visible bleeding or black stool requires clinical evaluation to identify the source; a negative FIT should not delay that evaluation.
Stool antigen and urea breath testing are common noninvasive active-infection tests. Selected biopsy-based tests are used during endoscopy. Blood antibody testing cannot reliably distinguish current from past infection and is not appropriate for confirming eradication.
Current ACG guidance recommends proof of eradication with an appropriately timed stool antigen, urea breath, or biopsy-based test at least four weeks after antibiotics. Acid-suppressing medicines can affect accuracy, so the timing and medication plan must follow professional and laboratory instructions.
It may be useful for severe, bloody, febrile, prolonged, travel-related, outbreak-associated, or immunocompromised diarrhea and when a result would change management or public-health action. It is not automatically necessary for every short, mild episode.
Pancreatic elastase-1 is measured in stool and is the preferred initial test when exocrine pancreatic insufficiency is suspected.13, 14 A formed or semiformed sample is important because watery stool can dilute the marker and produce a falsely low result.
No. Blood lipase and amylase are primarily used in a compatible acute pancreatitis evaluation.15, 25 Pancreatic elastase, selected fecal fat testing, nutritional assessment, imaging, and specialist-directed pancreatic-function testing address different chronic questions.
No. Some inflammatory, structural, microscopic, pancreatic, gallbladder, and malignant disorders may have normal routine blood work. Persistent warning symptoms may still require stool testing, imaging, endoscopy, colonoscopy, biopsy, or specialist evaluation.
They are not established replacements for validated celiac, allergy, IBD, infection, malabsorption, pancreatic, or structural evaluation.26 Proprietary scores may lack standardization and clear evidence that acting on the result improves outcomes.
Digestive health lab tests can help identify anemia, dehydration, inflammation, infection, celiac-associated antibodies, hidden blood, nutrient deficiency, and pancreatic or intestinal malabsorption. The most useful test depends on whether the question is systemic, intestinal, infectious, inflammatory, pancreatic, screening-related, or treatment-monitoring.
Focused testing is more informative than an indiscriminate panel, and no laboratory result replaces history, examination, imaging, endoscopy, biopsy, or urgent care when those are needed. Review results in context, confirm unexpected findings, and use trends only when the same clinical question is being followed. Explore the focused guides on celiac testing, IBD, IBS limitations, stool tests, H. pylori, lactose intolerance, nutrient absorption, pancreatitis, and pancreatic insufficiency to understand the next layer of evaluation.
Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.
Written by: John R. | Originally published: August 1, 2026 | Last updated: August 7, 2026
Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.
Complete Blood Count with Differential and Platelets,
Comprehensive Metabolic Panel,
C-Reactive Protein,
Sedimentation Rate,
Ferritin,
Iron and Total Iron Binding Capacity,
Transferrin,
Reticulocyte Count,
Vitamin B12,
Folate, Serum,
Vitamin D, 25-Hydroxy, Total,
Magnesium,
Zinc,
Ferritin, Iron, and TIBC Panel,
Vitamin B12 and Folate Panel,
Tissue Transglutaminase IgA Antibody,
Total IgA,
Endomysial IgA Antibody Screen with Reflex to Titer,
Deamidated Gliadin Peptide IgG and IgA Antibodies,
Tissue Transglutaminase IgG Antibody,
HLA Typing for Celiac Disease,
Celiac Disease Comprehensive Panel,
Celiac Disease – Comprehensive,
Calprotectin Stool Test,
Lactoferrin, Qualitative, Stool,
FIT Test,
Fecal Globin by Immunochemistry,
H. pylori Stool Antigen,
H. pylori Urea Breath Test,
Gastrointestinal Pathogen Panel,
Ova and Parasites Stool Examination,
Salmonella/Shigella Culture, Campylobacter EIA, and Shiga Toxin with Reflex,
C. difficile Toxin B,
Pancreatic Elastase-1,
Fecal Fat, Qualitative,
Lipase,
Amylase,.
Saccharomyces cerevisiae IgA Antibodies,
Saccharomyces cerevisiae IgG Antibodies,
ANCA Screen with Reflex to ANCA Titer,
Inflammatory Bowel Disease Differentiation Panel,
Liver Function Panel,
Hepatic Function Panel with GGT,
Direct Bilirubin,
Digestive Health – Basic,
Digestive Health – Advanced,
Inflammatory Bowel Disease – Basic,
Pancreatic Health Panel,
Gallbladder & Digestive Health Panel,
Nutrient Absorption & Deficiency Panel – Comprehensive,
Gut Health, Food Allergy & Nutrient Balance – Essential,
Gut Health, Food Allergy & Nutrient Balance – Advanced,
Gut Health, Food Allergy & Nutrient Balance – Comprehensive,
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
